What we have learned from the Optic Neuritis Treatment Trial

Journal article

Peer reviewed

R W Beck, J D Trobe and Optic Neuritis Study Group

Ophthalmology (Rochester, Minn.), Vol.102(10), pp.1504-1508

10/1995

DOI: 10.1016/S0161-6420(95)30839-1

PMID: 9097798

View Online

Clinical trial

Magnetic Resonance Imaging

Prednisolone - adverse effects

Multiple Sclerosis - diagnosis

Injections, Intravenous

Prednisolone - administration & dosage

Humans

Middle Aged

Male

Multiple Sclerosis - prevention & control

Anti-Inflammatory Agents - adverse effects

Anti-Inflammatory Agents - therapeutic use

Adult

Anti-Inflammatory Agents - administration & dosage

Female

Methylprednisolone Hemisuccinate - administration & dosage

Prednisolone - therapeutic use

Visual Acuity - physiology

Acute Disease

Methylprednisolone Hemisuccinate - therapeutic use

Administration, Oral

Treatment Outcome

Methylprednisolone Hemisuccinate - adverse effects

Optic Neuritis - physiopathology

Optic Neuritis - drug therapy

Adolescent

Brain - pathology

Multiple Sclerosis - etiology

Title: Subtitle: What we have learned from the Optic Neuritis Treatment Trial
Creators: R W Beck - Jaeb Center for Health Research, Inc., Tampa, FL 33613, USA
J D Trobe
Optic Neuritis Study Group
Resource Type: Journal article
Publication Details: Ophthalmology (Rochester, Minn.), Vol.102(10), pp.1504-1508
Publisher: United States
DOI: 10.1016/S0161-6420(95)30839-1
PMID: 9097798
ISSN: 0161-6420
eISSN: 1549-4713
Grant note: EYO7460 / NEI NIH HHS EYO7461 / NEI NIH HHS EYO7212 / NEI NIH HHS
Language: English
Date published: 10/1995
Academic Unit: Ophthalmology and Visual Sciences
Record Identifier: 9983980292202771

48 Record Views